Weight & metabolic
Liraglutide
GLP-1 Receptor Agonist (Daily)
One of the first GLP-1 receptor agonists approved for weight management. Requires daily injection but has the longest safety track record among GLP-1 drugs.
Also known as: Victoza, Saxenda
- Status
- Liraglutide is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- ~13 hours
- How it's taken
- Daily subcutaneous injection
- Mechanism
- Incretin (GLP-1 / GIP / glucagon / amylin)
- Pathways
- GLP-1
How Liraglutide works
Activates GLP-1 receptors to reduce appetite, slow gastric emptying, and improve blood sugar control. Works the same way as semaglutide but has a shorter half-life requiring daily dosing.
What research has looked at
- Long-established safety record
- FDA-approved for weight management (Saxenda)
- Also approved for type 2 diabetes (Victoza)
- Moderate but consistent weight loss
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Nausea (common)
- Diarrhea
- Constipation
- Low blood sugar when combined with other diabetes drugs
- Injection site reactions
- Rare: pancreatitis
Sources
- FDA approved-drug listing for liraglutide · U.S. Food & Drug Administration
- DailyMed prescribing information for liraglutide · NIH · DailyMed
- PubMed research on liraglutide weight management SCALE · NIH · National Library of Medicine
- DrugBank record for liraglutide · DrugBank
Track Liraglutide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Liraglutide FAQ
What is Liraglutide?
One of the first GLP-1 receptor agonists approved for weight management. Requires daily injection but has the longest safety track record among GLP-1 drugs.
How does Liraglutide work?
Activates GLP-1 receptors to reduce appetite, slow gastric emptying, and improve blood sugar control. Works the same way as semaglutide but has a shorter half-life requiring daily dosing.
Is Liraglutide FDA approved?
Yes. Liraglutide is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Liraglutide?
Reported half-life: ~13 hours.
How is Liraglutide taken?
Daily subcutaneous injection.
What side effects have been reported with Liraglutide?
Reported in the sources: Nausea (common); Diarrhea; Constipation; Low blood sugar when combined with other diabetes drugs; Injection site reactions; Rare: pancreatitis.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.